Drugs / Ferrous Bisglycinate
Ferrous Bisglycinate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03378791 | Dec 2015 → Oct 2017 | iron deficiency anemia | Hatem AbuHashim | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT03009578 Comparator | Feb 2017 → Apr 2018 | anemia | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT02590224 Comparator | Jan 2016 → Jul 2017 | iron deficiency anemia | Assiut University | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ferrous bis-glycinate | “Women will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets” NCT03009578 ↗ |
| Known as | Bisglycino-iron(ii) chelate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297753 ↗ |
| Known as | Ferrochel | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297753 ↗ |
| Known as | Ferrous glycinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297753 ↗ |
| Known as | Iron bis-glycinate chelate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297753 ↗ |
| Known as | Iron bisglycinate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03378791 ↗ |
| Known as | Pharaferro 27 tablets | “The patients will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets (Pharaferro 27 tablets) once daily for eight consecutive weeks.” NCT02590224 ↗ |
| Route | Oral | “The patients will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets (Pharaferro 27 tablets) once daily for eight consecutive weeks.” NCT02590224 ↗ |